Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Exposure to alloantigen in vivo or in vitro induces alloantigen reactive regulatory T cells that can control transplant rejection. The mechanisms that underpin the activity of alloantigen reactive regulatory T cells in vivo are common with those of regulatory T cells that prevent autoimmunity. The identification and characterization of regulatory T cells that control rejection and contribute to the induction of immunologic unresponsiveness to alloantigens in vivo has opened up exciting opportunities for new therapies in transplantation. Findings from laboratory studies are informing the design of clinical protocols using regulatory T cells as a cellular therapy.

Original publication

DOI

10.1111/j.1600-065X.2011.01013.x

Type

Journal article

Journal

Immunol Rev

Publication Date

05/2011

Volume

241

Pages

119 - 132

Keywords

Animals, Autoimmunity, Clinical Protocols, Graft Rejection, Humans, Immune Tolerance, Immunotherapy, Adoptive, Isoantigens, Organ Transplantation, T-Lymphocytes, Regulatory